Bibliography
- Rowland GF, O'Neill GJ, Davies DA. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 1975;255:487-8
- Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-7
- Getts DR, Getts MT, McCarthy DP, Have we overestimated the benefit of human(ized) antibodies? MAbs 2010;2:682-94
- Beerli RR, Rader C. Mining human antibody repertoires. MAbs 2010;2:365-78
- Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009;24:318-32
- Kuo TT, Baker K, Yoshida M, Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010;30:777-89
- Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226-43
- Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29:57-61
- Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34
- Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71
- Zahnd C, Kawe M, Stumpp MT, Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605
- Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
- Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 2011;3:848-83
- Doronina SO, Toki BE, Torgov MY, Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84
- Doronina SO, Mendelsohn BA, Bovee TD, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24
- Widdison WC, Wilhelm SD, Cavanagh EE, Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408
- Beusker PH, Coumans RGE, Elgersma RC, Novel conjugates of CC-1065 analogs and bifunctional linkers. WO2011133039A2; 2011
- Beusker PH, Spijker HJ, Joosten JAF, Preparation of substituted CC-1065 analogs and their conjugates for treating tumors. WO2009017394A1; 2009
- Gangwar S, Zhang Q. Preparation of CC-1065 analogs as potent cytotoxins and their intermediates. WO2007051081A1; 2007
- Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 2011;20:733-44
- Metz S, Haas AK, Daub K, Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011;108:8194-9
- Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002;54:487-504
- Hussain AF, Kampmeier F, von Felbert V, SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem 2011;22:2487-95
- Wakankar AA, Feeney MB, Rivera J, Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem 2010;21:1588-95
- White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001;52:125-45
- Al Ejeh F, Darby JM, Thierry B, Brown MP. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution. Nucl Med Biol 2009;36:395-402
- Shin IS, Lee SM, Kim HS, Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol 2011;38:1119-27
- Burris HA. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011;11:807-19
- LoRusso PM, Weiss D, Guardino E, Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47
- Wang L, Amphlett G, Blattler WA, Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005;14:2436-46
- Kinstler O, Molineux G, Treuheit M, Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477-85
- Manjappa AS, Chaudhari KR, Venkataraju MP, Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011;150:2-22
- Sun MM, Beam KS, Cerveny CG, Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005;16:1282-90
- Hofer T, Thomas JD, Burke TR Jr, Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci USA 2008;105:12451-6
- Junutula JR, Raab H, Clark S, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
- Lyons A, King DJ, Owens RJ, Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng 1990;3:703-8
- McDonagh CF, Kim KM, Turcott E, Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 2008;7:2913-23
- Stimmel JB, Merrill BM, Kuyper LF, Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J Biol Chem 2000;275:30445-50
- Voynov V, Chennamsetty N, Kayser V, Design and application of antibody cysteine variants. Bioconjug Chem 2010;21:385-92
- Baker TS, Humphreys DP, Lawson ADG. Altered human IgG antibodies and conjugates for disease diagnosis and therapy. WO2008038024A1; 2008
- Dimasi N, Gao C, Wu H. CH1 domain cysteine-substituted antibodies for site-specific conjugation and for diagnosis and treatment of inflammation, autoimmune disease, cancer or infection. WO2009092011A1; 2009
- Liu H, Chumsae C, Gaza-Bulseco G, Ranking the Susceptibility of Disulfide Bonds in Human IgG1 Antibodies by Reduction, Differential Alkylation, and LCMS Analysis. Anal Chem 2010;82:5219-26
- Gillies SD, Wesolowski JS. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibodies Hybridomas 1990;1:47-54
- Hamblett KJ, Senter PD, Chace DF, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70
- McDonagh CF, Turcott E, Westendorf L, Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006;19:299-307
- Junutula JR, Bhakta S, Raab H, Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 2008;332:41-52
- Humphreys DP, Heywood SP, Henry A, Alternative antibody Fab fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227-34
- Hamel PA, Klein MH, Dorrington KJ. The role of the VL- and VH-segments in the preferential reassociation of immunoglobulin subunits. Mol Immunol 1986;23:503-10
- Dillon TM, Ricci MS, Vezina C, Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008;283:16206-15
- Taylor FR, Prentice HL, Garber EA, Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem 2006;353:204-8
- Balan S, Choi JW, Godwin A, Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem 2007;18:61-76
- Mylotarg package insert: W10477C009 ET01. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf [Last accessed 3 March 2012]
- DiJoseph JF, Goad ME, Dougher MM, Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9
- Full Prescribing Information for Adcetris. Seattle Genetics, Inc. Available from: http://www.adcetris.com/_pdf/Final_Adcetris_USPI_Jan12_2012.pdf [Last accessed 3 March 2012]
- CDER Application No 125388Orig1s000 Chemistry Review(s). Center for Drug Evaluation and Research. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ChemR.pdf [Last accessed 3 March 2012]
- Shen BQ, Xu K, Liu L, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
- Hutchins BM, Kazane SA, Staflin K, Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem Biol 2011;18:299-303
- Kellogg BA, Garrett L, Kovtun Y, Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27
- Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13
- Derwin D, Passore D, Sung J, Activation of antibody drug conjugate MDX-1203 by Human Carboxylesterase 2. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 2575
- Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131-49
- Kovtun YV, Audette CA, Mayo MF, Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37
- Erickson HK, Park PU, Widdison WC, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
- Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85
- Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97
- Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982-1004
- Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009;1:443-52
- Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 2011;11:225-34
- Hutter ML, Schlenk RF. Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. Expert Opin Biol Ther 2011;11:1369-80
- Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27
- Bross PF, Beitz J, Chen G, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6
- Pfizer prepares for voluntary withdrawal of U.S. New drug application and for discontinuation of commercial availability Of Mylotarg®. Pfizer, Inc. Available from: http://www.pfizer.com/files/news/press_releases/2010/mylotarg_discontinuation_062110.pdf [Last accessed 3 March 2012]
- Pfizer prepares for voluntary withdrawal of U.S. New drug application and for discontinuation of commercial availability of mylotarg for relapsed acute myeloid leukemia. Pfizer, Inc. Available from: http://www.pfizer.com/files/products/mylotarg_hcp_letter.pdf [Last accessed 3 March 2012]
- S0106 Cytarabine and Daunorubicin with or without Gemtuzumab Ozogamicin Followed by high-dose cytarabine followed by either Gemtuzumab Ozogamicin or No additional therapy in treating patients with previously untreated De Novo acute myeloid leukemia. ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00085709?term=S0106&rank=1 [Last accessed 3 March 2012]
- Pautas C, Terre C, Raffoux E, Dombret H. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) improve event-free and overall survival in newly-diagnosed De Novo AML patients aged 50 – 70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). 2011
- ASH: Gemtuzumab—A Potential New Use for an Old Drug in AML. cancernetwork.com. Available from: http://www.cancernetwork.com/conference-reports/ash2011/content/article/10165/2005126 [Last accessed 3 March 2012]
- Pfizer's failed blood cancer drug shows benefits in study of new patients. BLOOMBERG L.P. Available from: http://www.bloomberg.com/news/2011-12-10/pfizer-s-failed-blood-cancer-drug-shows-benefits-in-study-of-new-patients.html [Last accessed 3 March 2012]
- Genentech Provides Update on FDA Application for T-DM1. Genentech, Inc. Available from: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12947 [Last accessed 3 March 2012]
- Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care in HER2-Positive Metastatic Breast Cancer. Genentech, Inc. Available from: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13607 [Last accessed 3 March 2012]
- Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer. F. Hoffmann-La Roche Ltd. Available from: http://www.roche.com/media/media_releases/med-cor-2012-03-30.htm [Last accessed 2 April 2012]
- An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA). ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT00829166 [Last accessed 3 March 2012]
- Ansell SM. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs 2011;20:99-105
- Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36
- Drug Approval Package: ADCETRIS (brentuximab vedotin). U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125399_adcetris_toc.cfm [Last accessed 3 March 2012]
- Briefing Information for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee. U.S. Food and Drug Administration. Available from: http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm262590.htm [Last accessed 3 March 2012]
- Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1:314-22
- Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010;2:256-65
- Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251-8
- A Study of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy. ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/show/NCT01232556 [Last accessed 3 March 2012]
- Genentech's Research and Early Development pipeline has over 30 new molecular entities in clinical development. Genentech, Inc. Available from: http://www.gene.com/gene/gred/science/pipeline/ [Last accessed 3 March 2012]
- Antibody-drug Conjugate Technology Collaborations. Seattle Genetics, Inc. Available from: http://www.seagen.com/collaborations_ADC.shtml [Last accessed 3 March 2012]
- Immunogen, Inc.: Securities and Exchange Commission form 8-K: Nov 29, 2011. Available from: http://www.faqs.org/sec-filings/111129/IMMUNOGEN-INC_8-K/ [Last accessed 3 March 2012]
- Morphosys 3rd Interim Report Oct 2011. Available from: http://www.morphosys.com/sites/default/files/111028_MOR-Q3-2011_e.pdf [Last accessed 3 March 2012]
- Wilex AG announces acquisition of Heidelberg Pharma AG. WILEX AG. Available from: http://www.wilex.de/pdf/Adhoc/2010/20101103_AH_WILEX_HDPAcquisition_eng.pdf [Last accessed 3 March 2012]
- Synthon acquires Syntarga and its Antibody-Drug Conjugate Technology. Synthon BV. Available from: http://www.synthon.com/en/nieuwsarchief/synthon-acquires-syntarga-and-its-antibody-drug-conjugate-technology.aspx [Last accessed 3 March 2012]
- Spirogen Ltd. announces a research collaboration and license agreement with Genentech for the discovery and development of antibody drug conjugates. Available from: http://www.spirogen.com/news/latest.php [Last accessed 3 March 2012]
- Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR. Seattle Genetics, Inc. Available from: http://www.businesswire.com/news/home/20120403006655/en/Seattle-Genetics-Demonstrates-Continued-Leadership-Antibody-Drug-Conjugates [Last accessed 23 April 2012]
- Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer. Available from: http://www.oxbt.co.uk/pdf/OBT_SGEN_20110913.pdf